BAKER BROS. ADVISORS LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001263508
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2025 · 88 positions · Total reported value $10.31B · Top-10 concentration 81.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 24.2% · 8 new · 6 cut · 8 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +14.7% · vs SPY -0.1% · Prev Value $16.51B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2025 13F filing, BAKER BROS. ADVISORS LP disclosed 88 equity positions with a combined reported value of $10.31B. The filing implies a focused portfolio: its ten largest positions account for 81.6% of reported value. HoldingsHub classifies the profile as Large / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2025 were ONC ($2.13B), INCY ($2.09B), ACAD ($925.28M). By sector, the heaviest allocations are Health Care 98.5%, Other 1.5%.
Versus the prior quarter, BAKER BROS. ADVISORS LP opened 8 new positions, trimmed 6 and fully exited 8, a turnover rate of 24.2% of positions. The portfolio's overlap with the prior quarter was 77% of names.
The largest new positions opened in Q2 2025 were VRDN ($24.39M), BPMC ($16.09M), ARWR ($14.84M).
Of the 8 positions fully exited versus the prior quarter, the largest were CRSP ($22.26M), CNTA ($17.65M), TSVT ($12.34M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2025)
Fully Exited (vs previous quarter)
- CRSP CRISPR THERAPEUTICS AG NAMEN AKT · prev qtr: $22.26M
- CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $17.65M
- TSVT 2SEVENTY BIO INC · prev qtr: $12.34M
- BCAX BICARA THERAPEUTICS INC · prev qtr: $10.86M
- IONS IONIS PHARMACEUTICALS INC · prev qtr: $10.80M · history
- DYN DYNE THERAPEUTICS INC · prev qtr: $7.03M
- RGLS REGULUS THERAPEUTICS INC · prev qtr: $4.71M
- PRME PRIME MEDICINE INC · prev qtr: $2.05M
Insider Transactions (Form 4)
Latest BAKER BROS. ADVISORS LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-06 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 2,000 | $396.61 | SEC filing |
| 2026-11-06 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 13,740 | $388.29 | SEC filing |
| 2026-11-06 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 60,400 | $383.01 | SEC filing |
| 2026-11-05 | Buy | Kodiak Sciences Inc. | 81,729 | $98.51 | SEC filing |
| 2026-11-05 | Buy | Kodiak Sciences Inc. | 4,703 | $98.51 | SEC filing |
| 2026-11-04 | Buy | Kodiak Sciences Inc. | 151,916 | $98.51 | SEC filing |
| 2026-11-04 | Buy | Kodiak Sciences Inc. | 8,742 | $98.51 | SEC filing |
| 2026-11-04 | Buy | MADRIGAL PHARMACEUTICALS, INC. | 10,080 | $368.11 | SEC filing |
Fund Profile
Baker BROS. Advisors is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 83 US equity positions with a combined value of $19.13B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-73446 (status: Approved), registered 2012-03-05
- Regulatory AUM (Form ADV): $28.15B as of 2026-03-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 2 hedge funds
Portfolio Structure
- 83 positions · $19.13B reported value (Q2 2026)
- Top 10 holdings = 74.7% of reported value
- Largest position: INCY (INCYTE CORP) at 18.2%
- Average position size: $230.45M
Sector Tilt
- Health Care 99.4%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 8 new, 10 added, 6 reduced, 8 exited
- 59 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
8.80M | $2.13B | 20.66% Form 4 · 1 → |
Hold | |
| 2 |
|
30.74M | $2.09B | 20.31% Form 4 · 1 → |
Hold | |
| 3 |
|
42.90M | $925.28M | 8.98% | Hold | |
| 4 |
|
7.71M | $776.23M | 7.53% | Add | |
| 5 |
|
33.72M | $717.62M | 6.96% | Add | |
| 6 |
|
1.98M | $598.02M | 5.80% Form 4 · 5 → |
Hold | |
| 7 |
|
5.60M | $354.15M | 3.44% | Hold | |
| 8 |
|
9.36M | $344.54M | 3.34% | Add | |
| 9 |
|
6.65M | $290.27M | 2.82% | Add | |
| 10 |
|
6.41M | $183.41M | 1.78% | Add | |
| 11 |
|
11.05M | $102.61M | 0.99% | Hold | |
| 12 |
|
2.77M | $100.82M | 0.98% | Add | |
| 13 |
|
7.31M | $95.78M | 0.93% | Add | |
| 14 |
|
27.53M | $94.41M | 0.92% | Hold | |
| 15 |
|
5.46M | $87.33M | 0.85% | Hold | |
| 16 |
|
1.63M | $83.82M | 0.81% | Hold | |
| 17 |
|
2.82M | $78.16M | 0.76% | Hold | |
| 18 |
|
10.89M | $75.65M | 0.73% | Hold | |
| 19 |
|
2.32M | $72.88M | 0.71% | Hold | |
| 20 |
|
5.45M | $72.76M | 0.71% | Add | |
| 21 |
|
17.31M | $64.57M | 0.63% Form 4 · 86 → |
Hold | |
| 22 |
|
10.17M | $54.71M | 0.53% | Add | |
| 23 |
|
4.63M | $52.59M | 0.51% | Hold | |
| 24 |
|
3.73M | $52.21M | 0.51% | Hold | |
| 25 |
|
2.51M | $52.03M | 0.51% | Add | |
| 26 |
|
2.12M | $44.54M | 0.43% | Add | |
| 27 |
|
3.88M | $44.22M | 0.43% | Hold | |
| 28 |
|
3.77M | $42.46M | 0.41% | Hold | |
| 29 |
|
368.92K | $39.28M | 0.38% | Add | |
| 30 |
|
4.87M | $32.70M | 0.32% | Hold | |
| 31 |
|
574.38K | $30.21M | 0.29% | Add | |
| 32 |
|
689.49K | $28.99M | 0.28% | Add | |
| 33 |
|
2.68M | $25.10M | 0.24% | Add | |
| 34 |
|
1.74M | $24.39M | 0.24% | New | |
| 35 |
|
4.92M | $22.17M | 0.21% | Hold | |
| 36 |
|
223.84K | $21.17M | 0.20% | Hold | |
| 37 |
|
640.88K | $20.84M | 0.20% | Hold | |
| 38 |
|
37.76K | $20.81M | 0.20% | Reduce | |
| 39 |
|
1.69M | $19.00M | 0.18% | Hold | |
| 40 |
|
12.88M | $18.17M | 0.18% | Reduce | |
| 41 |
|
337.05K | $17.85M | 0.17% | Add | |
| 42 |
|
324.63K | $17.32M | 0.17% | Reduce | |
| 43 |
|
125.54K | $16.09M | 0.16% | New | |
| 44 |
|
5.50M | $15.23M | 0.15% | Hold | |
| 45 |
|
939.17K | $14.84M | 0.14% | New | |
| 46 |
|
991.69K | $14.83M | 0.14% | Reduce | |
| 47 |
|
789.76K | $14.71M | 0.14% | New | |
| 48 |
|
665.37K | $13.54M | 0.13% | Add | |
| 49 |
|
1.46M | $13.39M | 0.13% | Hold | |
| 50 |
|
370.21K | $11.59M | 0.11% | Add | |
FAQ
What did BAKER BROS. ADVISORS LP buy in 2025-Q2?
In its 2025-Q2 13F filing, BAKER BROS. ADVISORS LP reported 88 equity positions worth $10.31B in aggregate; its largest disclosed positions were ONC ($2.13B), INCY ($2.09B), ACAD ($925.28M).
How large is BAKER BROS. ADVISORS LP's portfolio?
BAKER BROS. ADVISORS LP reported $10.31B of long equity holdings across 88 positions as of 2025-Q2. Top-10 holdings account for 81.6% of reported value.
What is BAKER BROS. ADVISORS LP's investment style?
HoldingsHub classifies the portfolio as Large / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.